The exclusion of other chronic liver diseases including “excess” alcohol intake has until now
been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population,
and has no approved drug therapy. Although pharmacotherapies are in development, …

Background Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentrations
of liver enzymes, and insulin resistance in murine models of fatty liver disease. These …

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects
approximately one-quarter of the global adult population, causing a substantial burden of ill …

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease
that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown …

Background Nonalcoholic steatohepatitis (NASH) is a common disease that is associated
with increased morbidity and mortality, but treatment options are limited. The efficacy and …

Liver diseases have become a major health threat across Europe, and the face of European
hepatology is changing due to the cure of viral hepatitis C and the control of chronic viral …

Background & Aims We estimated the accuracy of FibroScan vibration-controlled transient
elastography controlled attenuation parameter (CAP) and liver stiffness measurement (LSMs) …

The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to
healthcare systems in affected communities. Older patients and those with pre-existing medical …

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary
confounder terms and the use of potentially stigmatising language. This study set out to …